Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PENGUIN 2
  • Sponsors Gilead Sciences

Most Recent Events

  • 04 Jun 2022 Results assessing efficacy and safety of switching from filgotinib to tofacitinib in patients with psoriatic arthritis after 6 months of follow-up from two clinical studies: PENGUIN 1 and PENGUIN 2 and presented at the 23rd Annual Congress of the European League Against Rheumatism
  • 05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database record. (2021-03-18)
  • 05 May 2021 This trial has been completed in Czech Republic (End Date: 18 Mar 2021) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top